pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
Phase 2 · small molecule · Lymphoma
Ibrutinib (IMBRUVICA) is an oral small-molecule antineoplastic agent developed by Karyopharm Therapeutics Inc under internal code LY17, currently in Phase 2 development for lymphoma indications. The drug is a Bruton's tyrosine kinase (BTK) inhibitor, though specific mechanism and target details are not disclosed in ava
Internal code LY17
Ibrutinib (IMBRUVICA) is an oral small-molecule antineoplastic agent developed by Karyopharm Therapeutics Inc under internal code LY17, currently in Phase 2 development for lymphoma indications. The drug is a Bruton's tyrosine kinase (BTK) inhibitor, though specific mechanism and target details are not disclosed in available program intelligence. Ibrutinib has achieved regulatory approval in multiple major markets: the United States (NDA205552, NDA210563, NDA217003), European Union (EMEA/H/C/003791, authorized 13 February 2026), Japan (approved February 2023), and Australia (PBS-listed since December 2017). The program's most recent milestone is dated 20 April 2026, indicating ongoing development activity. Multiple generic and branded versions are marketed globally by sponsors including Janssen-Cilag, Alvogen, Sandoz, Teva, and Zydus Lifesciences, reflecting the drug's established commercial presence. The Phase 2 trial NCT02436707 represents the current active clinical investigation under Karyopharm's sponsorship, though detailed trial outcomes remain not yet disclosed.
Lymphoma represents a significant oncology market with substantial unmet medical need across multiple histological subtypes. Ibrutinib addresses this market as an oral BTK inhibitor offering potential advantages in tolerability and convenience compared to intravenous chemotherapy regimens. The drug's approval across US, EU, Japan, and Australia demonstrates established clinical validation and regulatory acceptance, positioning it as a standard-of-care option in multiple lymphoma settings. The competitive landscape includes multiple targeted agents (KYPROLIS, AFINITOR, INLYTA) and chemotherapy-based regimens, yet ibrutinib maintains market relevance through its oral bioavailability and established safety profile. Karyopharm's Phase 2 program suggests investigation of novel indications or patient populations not yet disclosed, potentially targeting treatment-resistant disease or earlier-line settings. The presence of multiple generic manufacturers indicates mature market penetration and pricing pressure, yet continued clinical development by Karyopharm suggests potential label expansion opportunities. Patient populations with relapsed/refractory lymphoma or specific molecular subtypes represent key commercial targets, with global peak sales potential driven by adoption across developed and emerging markets.
Drug Class: Antineoplastic and immunomodulating agent (ATC L01)
Modality: Small-molecule oral agent
Route of Administration: Oral
Brand Name: IMBRUVICA
International Nonproprietary Name (INN): Ibrutinib
Mechanism of Action: Not disclosed in program intelligence; however, ibrutinib is established as a Bruton's tyrosine kinase (BTK) inhibitor in clinical practice.
Target: Not disclosed in program intelligence.
Related Therapies: Other BTK inhibitors, proteasome inhibitors (KYPROLIS), mTOR inhibitors (AFINITOR), tyrosine kinase inhibitors (INLYTA, ARX-IMATINIB), and conventional chemotherapy regimens.
First Approval: United States (NDA205552); subsequent approvals in EU, Japan, and Australia documented from 2017 onwards.
Patent Status: Not disclosed in program intelligence.
Also known as: lymphoma (Hodgkin and non-Hodgkin), lymphoma (Hodgkin's and non-Hodgkin's), lymphoma, malignant, lymphomatous, malignant lymphoma, MLYM
A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
ClinicalTrials.gov lists 16 registered studies for Lymphoma, Hodgkin (AACT aggregate).
Phase breakdown: NA (10), PHASE1 (3), PHASE2 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005062), Orphanet — lymphoma, NCT00026208, NCT00578461, NCT01459224, NCT02996773, NCT03117036, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Australia TGA approval
Ibrutinib listed on Australian Register of Therapeutic Goods (ARTG) with PBS codes 11213E and 11419B.
Australia PBS expansion
Additional PBS codes assigned (14074R, 14075T, 14079B, 14085H, 14086J, 14579H, 14580J, 14596F) indicating label or reimbursement expansion.
Japan PMDA approval
Ibrutinib approved by Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
Australia additional listing
Further PBS listing update recorded for ibrutinib in Australia.
EU EMA authorization
European Medicines Agency (EMA) granted marketing authorization for ibrutinib (EMEA/H/C/003791).
Latest Karyopharm milestone
Most recent program milestone recorded for Karyopharm's Phase 2 lymphoma trial (NCT02436707); specific milestone details not disclosed.
Ibrutinib competes within a diverse lymphoma treatment landscape spanning multiple drug classes and mechanisms. Approved competitors identified include KYPROLIS (carfilzomib, Amgen; proteasome inhibitor), AFINITOR (everolimus, Novartis; mTOR inhibitor), INLYTA (axitinib, Pfizer; tyrosine kinase inhibitor), and ARX-IMATINIB (imatinib, Alphapharm; tyrosine kinase inhibitor). Chemotherapy-based regimens such as PACLITAXEL ACCORD (Accord Healthcare) and EVOLTRA (clofarabine, Amneal Pharma) represent conventional alternatives. Targeted agents including LYNOZYFIC (selinexor, Regeneron), VYXEOS LIPOSOMAL (daunorubicin/cytarabine, Jazz Pharmaceuticals), UNITUXIN (dinutuximab, United Therapeutics), LYSODREN (mitotane), and OFEV (nintedanib, Boehringer Ingelheim) address specific lymphoma subtypes or disease stages. Ibrutinib's competitive advantage derives from its oral bioavailability, established safety profile across multiple approvals, and mature clinical evidence base. However, the presence of multiple generic manufacturers (Alvogen, Sandoz, Teva, Zydus) indicates commoditization and pricing pressure. Karyopharm's ongoing Phase 2 development suggests potential differentiation through novel indications, patient populations, or combination strategies not yet disclosed, positioning the program to address residual unmet needs in treatment-resistant or early-line lymphoma settings.
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Ibrutinib approved via multiple NDAs (NDA205552, NDA210563, NDA217003) with multiple generic ANDAs approved (ANDA211267, ANDA211344, ANDA211350, ANDA212763, ANDA214296, ANDA214498, ANDA215464) from sponsors including Alvogen, Sandoz, Teva, and Zydus Lifesciences, indicating mature market with established generic competition.
European Union (EMA): Marketing authorization granted 13 February 2026 (EMEA/H/C/003791) with Marketing Authorization Holder (MAH) Janssen-Cilag International NV.
Japan (PMDA): Approved February 2023 by the Pharmaceuticals and Medical Devices Agency.
Australia (TGA): Registered on Australian Register of Therapeutic Goods (ARTG) with initial listing December 2017; PBS-reimbursed with multiple codes (11213E, 11419B, 14074R, 14075T, 14079B, 14085H, 14086J, 14579H, 14580J, 14596F) indicating multiple indications or patient populations; sponsor Janssen-Cilag Pty Ltd.
China (NMPA): Clinical trials ongoing (NCT03734016, NCT07377578); regulatory approval status not yet disclosed.
Ibrutinib is an oral antineoplastic agent approved for lymphoma treatment. Specific approved indications vary by country and are not detailed in available program intelligence; however, the drug is established as a standard-of-care BTK inhibitor across multiple lymphoma subtypes.
Yes, ibrutinib is FDA-approved via multiple NDAs (NDA205552, NDA210563, NDA217003), with multiple generic versions also approved (ANDA211267, ANDA211344, ANDA211350, ANDA212763, ANDA214296, ANDA214498, ANDA215464).
The brand name is IMBRUVICA, marketed globally by Janssen-Cilag and multiple generic manufacturers.
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B-cell malignancies. Specific mechanism of action details are not disclosed in available program intelligence.
Ibrutinib is administered orally as a small-molecule tablet or capsule formulation.
Ibrutinib is manufactured by multiple companies including Janssen-Cilag (branded IMBRUVICA), Alvogen, Sandoz, Teva Pharmaceuticals, and Zydus Lifesciences (generic versions).
Yes, the European Medicines Agency (EMA) granted marketing authorization on 13 February 2026 (EMEA/H/C/003791) with Janssen-Cilag International NV as the Marketing Authorization Holder.
Yes, ibrutinib was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in February 2023.
Yes, ibrutinib is registered on the Australian Register of Therapeutic Goods (ARTG) with PBS reimbursement since December 2017, with multiple PBS codes indicating multiple indications or patient populations.
Karyopharm Therapeutics is conducting Phase 2 trial NCT02436707 for lymphoma; additional trials are ongoing in China (NCT03734016, NCT07377578). Detailed trial results are not yet disclosed in available program intelligence.
Karyopharm Therapeutics is sponsoring a Phase 2 lymphoma trial (NCT02436707) with the most recent milestone dated 20 April 2026, indicating ongoing development beyond established approvals.
Competitors include KYPROLIS (proteasome inhibitor), AFINITOR (mTOR inhibitor), INLYTA (tyrosine kinase inhibitor), LYNOZYFIC (selinexor), VYXEOS LIPOSOMAL, and conventional chemotherapy regimens such as PACLITAXEL ACCORD.
Yes, multiple generic versions are FDA-approved and marketed by Alvogen, Sandoz, Teva, and Zydus Lifesciences, indicating mature generic competition.
The internal code is LY17.
Regulatory approval status in China is not yet disclosed; however, clinical trials are ongoing (NCT03734016, NCT07377578).
Ibrutinib is classified as an antineoplastic and immunomodulating agent (ATC L01) and is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor.
Ibrutinib → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Karyopharm's Phase 2 program (NCT02436707) with latest milestone dated 20 April 2026 indicates active development beyond ibrutinib's established approvals, suggesting investigation of novel indications, patient populations, or combination approaches in lymphoma. The program's continuation despite mature market presence and generic competition implies potential for label expansion or differentiated positioning in treatment-resistant disease.
Competitive Implications: Multiple generic manufacturers (Alvogen, Sandoz, Teva, Zydus) have captured significant market share, creating pricing pressure on branded versions. Karyopharm's Phase 2 development may target niche indications with reduced generic competition or earlier-line settings where branded positioning remains viable. The competitive landscape includes diverse mechanisms (BTK inhibition, proteasome inhibition, mTOR inhibition, conventional chemotherapy), yet ibrutinib's oral convenience and established safety profile maintain clinical relevance.
Future Catalysts: Completion and readout of NCT02436707 represents the primary near-term catalyst; timing not yet disclosed. Potential regulatory submissions based on Phase 2 data could drive label expansion in US, EU, and other markets. International expansion in China (clinical trials ongoing) and other emerging markets may provide growth opportunities. Patent expiration timelines and generic market dynamics will influence commercial strategy.
Expected Milestones: Phase 2 trial completion and data readout; regulatory submissions for label expansion; potential combination therapy approvals; geographic expansion in China and other markets. Specific timelines not yet disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.